Qiagen N.V. (QGEN) : The highest short term price target forecast on Qiagen N.V. (QGEN) is $27 and the lowest target price is $24. A total of 6 equity analysts are currently covering the company. The average price of all the analysts is $25.25 with a standard deviation of $1.08.
Qiagen N.V. (QGEN) : Zacks Investment Research ranks Qiagen N.V. (QGEN) as 2, which is a Buy recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 11 research analysts is 2.59, which indicates as a Hold.
Also, HSBC upgrades its rating on Qiagen N.V. (NASDAQ:QGEN). Analysts at the HSBC have a current rating of Buy on the shares. The shares were previously rated Hold. The rating by the firm was issued on August 1, 2016.
Qiagen N.V. (NASDAQ:QGEN): The stock opened at $26.41 on Thursday but the bulls could not build on the opening and the stock topped out at $26.49 for the day. The stock traded down to $26.33 during the day, due to lack of any buying support eventually closed down at $26.46 with a loss of -0.19% for the day. The stock had closed at $26.51 on the previous day. The total traded volume was 832,765 shares.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.